Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer.

Wan Xing HongIdit Sagiv-BarfiDebra K CzerwinskiAdrienne Sallets Ronald Levy

Published in: Cancer research (2022)

This work demonstrates the ability of neoadjuvant intratumoral immunotherapy to target local and distant metastatic disease and consequently improve survival.

Keyphrases

lymph node
rectal cancer
locally advanced
squamous cell carcinoma
small cell lung cancer
papillary thyroid
toll like receptor
inflammatory response
immune response
squamous cell
free survival
radiation therapy
nuclear factor
childhood cancer